Editas Medicine (EDIT) News Today $2.63 -0.10 (-3.66%) Closing price 08/19/2025 04:00 PM EasternExtended Trading$2.70 +0.08 (+2.85%) As of 07:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EDIT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Editas Medicine (NASDAQ:EDIT) Downgraded to Sell Rating by Wall Street ZenAugust 17 at 2:56 AM | marketbeat.comWhy Editas Medicine Stock Was Skyrocketing This WeekAugust 16, 2025 | msn.comEditas Medicine (NASDAQ:EDIT) Posts Earnings Results, Misses Expectations By $0.22 EPSAugust 15, 2025 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Price Target Raised to $6.00August 15, 2025 | marketbeat.comEditas Medicine price target raised to $6 from $4 at BairdAugust 13, 2025 | msn.comEditas Medicine, Inc.: Editas Medicine Announces Second Quarter 2025 Results and Business UpdatesAugust 13, 2025 | finanznachrichten.deCan This Beaten-Down Stock Bounce Back?August 12, 2025 | msn.comEditas Medicine Announces Second Quarter 2025 Results and Business UpdatesAugust 12, 2025 | globenewswire.comAnalysts Set Editas Medicine, Inc. (NASDAQ:EDIT) PT at $4.70August 9, 2025 | americanbankingnews.comGinkgo Bioworks files $500M mixed securities shelfAugust 8, 2025 | msn.comXTX Topco Ltd Buys 370,325 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)August 7, 2025 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Hold" from AnalystsAugust 6, 2025 | marketbeat.comInsider Selling: Editas Medicine, Inc. (NASDAQ:EDIT) EVP Sells $12,751.29 in StockAugust 5, 2025 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) EVP Sells $12,751.29 in StockAugust 5, 2025 | insidertrades.comEditas Medicine (EDIT) Expected to Announce Earnings on WednesdayJuly 31, 2025 | marketbeat.comEditas Medicine: Primed For An Unlikely Comeback? It's Not ImpossibleJuly 30, 2025 | seekingalpha.comEditas Medicine (NASDAQ:EDIT) Raised to Hold at Wall Street ZenJuly 26, 2025 | marketbeat.comEditas Surpasses Therapeutic Gene Editing Threshold in New Preclinical DataJuly 3, 2025 | msn.comEditas Medicine Inc EDIT Company Vitals - U.S. NewsJuly 1, 2025 | money.usnews.comSickle Cell Disease Treatment Market Set for Robust Growth Through 2034, Driven by Recent Clinical Pipeline Developments | DelveInsightJuly 1, 2025 | theglobeandmail.comWall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?June 28, 2025 | fool.comEditas Medicine (NASDAQ:EDIT) Upgraded by Wall Street Zen to Hold RatingJune 27, 2025 | marketbeat.comEditas Medicine Inc. Annual Cash Flow Statement - MarketWatchJune 25, 2025 | marketwatch.comEditas Medicine Inc.June 25, 2025 | barrons.comGene editors steady despite latest leadership shake-up at FDAJune 20, 2025 | msn.comLilly-Verve deal sends gene editing stocks higherJune 17, 2025 | msn.comEditas Medicine Is Great. Here's Why You Shouldn't Buy It.June 17, 2025 | msn.comEditas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of "Hold" from BrokeragesJune 17, 2025 | marketbeat.comEditas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in JuneJune 12, 2025 | globenewswire.comRFK Jr. Just Supercharged These 2 Biotech Penny StocksJune 11, 2025 | msn.comBank of America Corp DE Reduces Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT)June 11, 2025 | marketbeat.comCantor Fitzgerald Comments on Editas Medicine FY2026 EarningsJune 10, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Position in Editas Medicine, Inc. (NASDAQ:EDIT)June 9, 2025 | marketbeat.comAmeriprise Financial Inc. Purchases 168,134 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)June 6, 2025 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 15,192 SharesJune 5, 2025 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) CEO Sells $26,130.24 in StockJune 5, 2025 | insidertrades.comEditas Medicine Q2 EPS Estimate Increased by Zacks ResearchJune 4, 2025 | marketbeat.comEditas Medicine Stockholders Approve Key AmendmentsJune 2, 2025 | tipranks.comEditas Medicine, Inc. (NASDAQ:EDIT) Short Interest Down 21.7% in MayJune 2, 2025 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) Shares Bought by Two Sigma Investments LPJune 2, 2025 | marketbeat.comMillennium Management LLC Cuts Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT)June 1, 2025 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) Shares Bought by Two Sigma Advisers LPMay 30, 2025 | marketbeat.comEditas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exitMay 28, 2025 | seekingalpha.com1 Stock Down 97% That Could Double, According to Wall StreetMay 25, 2025 | fool.comEditas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of "Hold" by BrokeragesMay 25, 2025 | marketbeat.com400,000 Shares in Editas Medicine, Inc. (NASDAQ:EDIT) Bought by Tang Capital Management LLCMay 21, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Boosts Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT)May 19, 2025 | marketbeat.comEditas Medicine reports breakthrough in liver disease treatmentMay 15, 2025 | uk.investing.comEditas Medicine: A Cautionary Tale for InvestorsMay 15, 2025 | fool.comEditas Medicine at BofA Securities 2025: In Vivo Gene Editing FocusMay 15, 2025 | investing.com Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address EDIT Media Mentions By Week EDIT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EDIT News Sentiment▼-0.320.47▲Average Medical News Sentiment EDIT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EDIT Articles This Week▼74▲EDIT Articles Average Week Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Beam Therapeutics News Today CRISPR Therapeutics News Today Intellia Therapeutics News Today Praxis Precision Medicines News Today Iovance Biotherapeutics News Today Oric Pharmaceuticals News Today Nuvation Bio News Today Upstream Bio News Today Trevi Therapeutics News Today Urogen Pharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EDIT) was last updated on 8/20/2025 by MarketBeat.com Staff From Our PartnersWinning the AI WarWhat’s really driving the trade wars, reshoring, and sweeping executive orders? According to Porter Stansberry...Porter & Company | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSeptember 16 Could Crush Your Tech StocksMillions of investors are piled into the same megacap tech stocks—Nvidia, Microsoft, Amazon, Tesla. But Wall S...InvestorPlace | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access